{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jones GS"],"funding":["Intramural NIH HHS","National Cancer Institute"],"pagination":["227-229.e2"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8529633"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["Nonalcoholic fatty liver disease (NAFLD) is a global public health problem linked to the rising prevalence of obesity and metabolic disorders.<sup>1</sup> Accurate estimates of NAFLD in populations are challenging because the gold standard for detection is liver biopsy, an invasive procedure that precludes its use in research settings.<sup>2</sup> NAFLD can also be detected via noninvasive imaging, such as ultrasound, magnetic resonance imaging-determined proton density fat fraction, magnetic resonance spectroscopy, and the controlled attenuation parameter derived via transient elastography (CAP-TE).<sup>2</sup> Given the complexities of imaging in population studies, however, many estimates have been based on calculated indices, such as the Fatty Liver Index (FLI)<sup>3</sup> and the Hepatic Steatosis Index (HSI).<sup>4</sup> Concern has been raised that the indices underestimate the prevalence of NAFLD,<sup>5</sup> thus downplaying the scope of the public health challenge. Ability to examine whether these concerns are substantive has been provided by a recent study of the US population. Using data from the study, it was reported that the US prevalence of CAP-TE-determined NAFLD was 47.8%.<sup>6</sup> The current analysis used data from the same national study to examine how well the fatty liver indices corresponded to CAP-TE-determined NAFLD. Because most persons with NAFLD reportedly have elevated alanine aminotransferase (ALT) levels,<sup>7</sup> the correspondence between elevated ALT and CAP-TE was also examined."],"journal":["Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"],"pubmed_title":["Agreement Between the Prevalence of Nonalcoholic Fatty Liver Disease Determined by Transient Elastography and Fatty Liver Indices."],"pmcid":["PMC8529633"],"funding_grant_id":["ZIA CP010158"],"pubmed_authors":["Graubard BI","Alvarez CS","McGlynn KA","Jones GS"],"additional_accession":[]},"is_claimable":false,"name":"Agreement Between the Prevalence of Nonalcoholic Fatty Liver Disease Determined by Transient Elastography and Fatty Liver Indices.","description":"Nonalcoholic fatty liver disease (NAFLD) is a global public health problem linked to the rising prevalence of obesity and metabolic disorders.<sup>1</sup> Accurate estimates of NAFLD in populations are challenging because the gold standard for detection is liver biopsy, an invasive procedure that precludes its use in research settings.<sup>2</sup> NAFLD can also be detected via noninvasive imaging, such as ultrasound, magnetic resonance imaging-determined proton density fat fraction, magnetic resonance spectroscopy, and the controlled attenuation parameter derived via transient elastography (CAP-TE).<sup>2</sup> Given the complexities of imaging in population studies, however, many estimates have been based on calculated indices, such as the Fatty Liver Index (FLI)<sup>3</sup> and the Hepatic Steatosis Index (HSI).<sup>4</sup> Concern has been raised that the indices underestimate the prevalence of NAFLD,<sup>5</sup> thus downplaying the scope of the public health challenge. Ability to examine whether these concerns are substantive has been provided by a recent study of the US population. Using data from the study, it was reported that the US prevalence of CAP-TE-determined NAFLD was 47.8%.<sup>6</sup> The current analysis used data from the same national study to examine how well the fatty liver indices corresponded to CAP-TE-determined NAFLD. Because most persons with NAFLD reportedly have elevated alanine aminotransferase (ALT) levels,<sup>7</sup> the correspondence between elevated ALT and CAP-TE was also examined.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-26T00:22:10Z","creation":"2025-04-06T09:44:05.903Z"},"accession":"S-EPMC8529633","cross_references":{"pubmed":["33227430"],"doi":["10.1016/j.cgh.2020.11.028"]}}